Trial Profile
A Randomised, DB, Placebocontrolled, Multicentre, Multinational Phase II/III Study to Assess the Efficacy and Safety of Three Different Dose Regimens of Oralgen Grasspollen in Patients With Grasspollen Related Allergic Rhinoconjunctivitis.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
- Focus Registrational; Therapeutic Use
- 21 Dec 2007 New trial record.